Export 17 results:
Author Title Type [ Year
Filters: Author is Michael, Nelson L [Clear All Filters]
“Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.”, N Engl J Med, vol. 361, no. 23, pp. 2209-20, 2009.
, “Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.”, PLoS One, vol. 6, no. 12, p. e27837, 2011.
, “Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: a post-hoc analysis of the Thai phase 3 efficacy trial RV 144.”, Lancet Infect Dis, vol. 12, no. 7, pp. 531-7, 2012.
, “The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.”, J Immunol, vol. 188, no. 10, pp. 5166-76, 2012.
, “Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys.”, Nature, vol. 482, no. 7383, pp. 89-93, 2012.
, “Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand.”, PLoS One, vol. 10, no. 5, p. e0127998, 2015.
, “Epidemiology of HIV among US Air Force Military Personnel, 1996-2011.”, PLoS One, vol. 10, no. 5, p. e0126700, 2015.
, , “Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies.”, Hepatology, vol. 63, no. 2, pp. 398-407, 2016.
, “Knowledge, attitudes, and beliefs about HIV pre-exposure prophylaxis among US Air Force Health Care Providers.”, Medicine (Baltimore), vol. 95, no. 32, p. e4511, 2016.
, “Prospective Study of Acute HIV-1 Infection in Adults in East Africa and Thailand.”, N Engl J Med, vol. 374, no. 22, pp. 2120-30, 2016.
, “Clinical indicators associated with HIV acquisition in the United States Air Force.”, AIDS Care, vol. 29, no. 6, pp. 724-728, 2017.
, ,
“Biomarkers of Inflammation Correlate With Clinical Scoring Indices in Human Immunodeficiency Virus-Infected Kenyans.”, J Infect Dis, vol. 219, no. 2, pp. 284-294, 2019.
, “Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.”, Lancet HIV, vol. 6, no. 5, pp. e297-e306, 2019.
, “Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.”, Lancet Infect Dis, vol. 19, no. 9, pp. 1013-1022, 2019.
, “A vaccine-induced gene expression signature correlates with protection against SIV and HIV in multiple trials.”, Sci Transl Med, vol. 11, no. 507, 2019.
,